ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Coronavirus

Wuhan hospital chief dies, marking 2nd prominent doctor killed by virus

Liu Zhiming succumbs to coronavirus after fighting outbreak at its epicenter

BEIJING (Reuters) -- The head of a leading hospital in China's central city of Wuhan, the epicentre of a coronavirus outbreak, died of the disease on Tuesday, state television said, becoming the second prominent Chinese doctor to have succumbed to the pathogen.

Liu Zhiming, the director of Wuhan Wuchang Hospital, died at 10:30 a.m., it said.

Earlier this month, millions in China mourned the death of Li Wenliang, a doctor who was previously reprimanded for issuing an early warning about the coronavirus.

Tens of thousands of medical workers have been fighting to contain the spread of the coronavirus, believed to have first surfaced in a seafood market in Wuhan, the capital of the central province of Hubei.

As in the case of Li's death, there was confusion on the Chinese internet about Liu's condition on Monday night.

On Monday night, the Communist Party propaganda department of the Hubei Health Commission wrote in a social media post that Liu had died.

But it said in a subsequent post that Liu was alive.

"According to Liu's relative, the hospital is still trying its best to rescue him," the commission said in the second post, adding that the previous misinformation was from a good friend of Liu who was not aware of the latest situation.

It has not posted any message since state television announced Liu's death on Tuesday morning.

Beijing was accused of covering up the full extent of the Severe Acute Respiratory Syndrome (SARS) outbreak in 2003. In the current coronavirus outbreak, Beijing has called for transparency.

A senior Chinese health official said on Friday that 1,716 health workers have been infected by the coronavirus and six of them have died.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media